Vertex Pharmaceuticals Profile

Performance

1818

Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for Vertex Pharmaceuticals Incorpor are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 13, 2019 and ending today December 12, 2019. Click here to learn more.

Vertex Pharmaceuticals Profile

Next fiscal quarter end is expected on December 31, 2019. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people. more
NameVertex Pharmaceuticals Incorpor
ChairmanJoshua BogerView All
Thematic Classification
Currently Active Investing Idea
  Biotech
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
Business Address50 Northern Avenue, Boston, MA 02210, United States
Foreign Associates
ExchangeBATS Exchange
CIK Number0000875320
ISINUS92532F1003
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.vrtx.com
Phone617 341 6100
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestNovember 15, 2019
Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people. The company currently falls under 'Large-Cap' category with current market capitalization of 56.64 B. Vertex Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 257.15 M outstanding shares of which 4 M shares are at this time shorted by private and institutional investors with about 2.73 trading days to cover. VERTEX PHARMACEUT currently holds about 4 B in cash with 1.07 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.54.
Check Vertex Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Vertex Pharmaceuticals Target Price Odds Analysis

Odds Below 220.55HorizonTargetOdds Above 220.55
91.52%30 days 220.55 8.42%
Based on normal probability distribution, the odds of Vertex Pharmaceuticals to move above current price in 30 days from now is about 8.42 (This Vertex Pharmaceuticals Incorpor probability density function shows the probability of Vertex Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Vertex Pharmaceuticals Top Holders

Vertex Pharmaceuticals Incorpor Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Vertex Pharmaceuticals Key Fundamentals

Vertex Pharmaceuticals Against Markets

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Vertex Pharmaceuticals Upcoming and Recent Events

Vertex Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 4, 2020
Next Earnings ReportMay 5, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 4, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Vertex Pharmaceuticals Corporate Filings

Vertex Pharmaceuticals SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Entry into a Material Definitive Agreement
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement

Vertex Pharmaceuticals Corporate Directors

William Young Independent Director
Alan Garber Independent Director
Margaret McGlynn Independent Director
Also please take a look at World Market Map. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Search macroaxis.com